184 related articles for article (PubMed ID: 25905781)
1. Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.
Wang D; Li Z; Xiao J; Wang J; Zhang L; Liu Y; Fan F; Xin L; Wei M; Kong Z; Yu H; Gu Y; Zhang J; Li S; Xia N
PLoS One; 2015; 10(4):e0123944. PubMed ID: 25905781
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
3. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
4. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
5. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
6. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
Front Immunol; 2020; 11():606569. PubMed ID: 33343580
[TBL] [Abstract][Full Text] [Related]
7. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
[TBL] [Abstract][Full Text] [Related]
8. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
[TBL] [Abstract][Full Text] [Related]
9. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
10. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
[TBL] [Abstract][Full Text] [Related]
11. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
12. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
13. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
Godi A; Bissett SL; Miller E; Beddows S
J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
[TBL] [Abstract][Full Text] [Related]
14. A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types.
Zhang T; Chen X; Liu H; Bao Q; Wang Z; Liao G; Xu X
Vaccine; 2019 Jul; 37(30):4022-4030. PubMed ID: 31213378
[TBL] [Abstract][Full Text] [Related]
15. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
[TBL] [Abstract][Full Text] [Related]
16. Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.
Godi A; Facchetti A; Bissett SL; Cocuzza C; Miller E; Beddows S
J Virol; 2015 Dec; 90(6):3247-52. PubMed ID: 26719255
[TBL] [Abstract][Full Text] [Related]
17. Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.
Bywaters SM; Brendle SA; Biryukov J; Wang JW; Walston J; Milici J; Roden RB; Meyers C; Christensen ND
Virology; 2018 Nov; 524():106-113. PubMed ID: 30170240
[TBL] [Abstract][Full Text] [Related]
18. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
[TBL] [Abstract][Full Text] [Related]
19. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.
Gambhira R; Jagu S; Karanam B; Gravitt PE; Culp TD; Christensen ND; Roden RB
J Virol; 2007 Nov; 81(21):11585-92. PubMed ID: 17715230
[TBL] [Abstract][Full Text] [Related]
20. Development of human papillomavirus chimaeric L1/L2 candidate vaccines.
McGrath M; de Villiers GK; Shephard E; Hitzeroth II; Rybicki EP
Arch Virol; 2013 Oct; 158(10):2079-88. PubMed ID: 23636405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
